Patents Examined by Tracy Vivlemore
  • Patent number: 10844428
    Abstract: The disclosed embodiments concern methods, apparatus, systems and computer program products for determining sequences of interest using unique molecular index (UMI) sequences that are uniquely associable with individual polynucleotide fragments, including sequences with low allele frequencies and long sequence length. In some implementations, the UMIs include both physical UMIs and virtual UMIs. In some implementations, the unique molecular index sequences include non-random sequences. System, apparatus, and computer program products are also provided for determining a sequence of interest implementing the methods disclosed.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: November 24, 2020
    Assignee: Illumina, Inc.
    Inventors: Sante Gnerre, Byoungsok Jung, Emrah Kostem, Alex Aravanis, Alex So, Xuyu Cai, Zhihong Zhang, Frank J. Steemers
  • Patent number: 10844383
    Abstract: The microRNA dyslipidemia inhibitor includes methods of administering a miRNA capable of inhibiting dyslipidemia to a subject in need thereof. The methods of the miRNA dyslipidemia inhibitor may include administration of miRNA-103 to a subject in need thereof. The administration of miRNA-103 may inhibit ANGPTL8 activity, thereby reducing ANGPTL8's inhibition of lipoprotein lipase activity and increasing triglyceride degradation. The administration of miRNA-103 may be used to treat or prevent lipid metabolism disorders including dyslipidemia and dyslipidemia associated diseases, such as hyperlipidemia, atherosclerosis, heart disease, and the like.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: November 24, 2020
    Assignee: DASMAN DIABETES INSTITUTE
    Inventors: Mohamed Abufarha, Jehad Abubaker, Fahd Al Mulla, Preethi Cherian, Irina Alkhairi
  • Patent number: 10842812
    Abstract: Methods of promoting hypoxia or the hypoxia response for the treatment or prevention of mitochondrial dysfunction and oxidative stress disorders are described. Methods for screening for targets of mitochondrial dysfunction and oxidative stress disorders are also described.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: November 24, 2020
    Assignees: The General Hospital Corporation, Massachusetts Institute of Technology
    Inventors: Vamsi K. Mootha, Isha Jain, Warren M. Zapol, Luca Zazzeron
  • Patent number: 10844377
    Abstract: Provided are compositions and methods comprising two-tailed siRNAs (tt-siRNAs) that exhibit unprecedented cellular uptake and silencing. Also provided are methods of treating neurological and other diseases with the two-tailed siRNAs of the invention.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: November 24, 2020
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Anastasia Khvorova, Julia Alterman, Matthew Hassler
  • Patent number: 10837883
    Abstract: The present invention generally relates to systems and methods to create stable emulsions with low rates of exchange of molecules between microdroplets.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: November 17, 2020
    Assignees: Bio-Rad Laboratories, Inc., University of Strasbourg
    Inventors: Felix Kleinschmidt, Andrew David Griffiths, François Caron, Abdeslam El Harrak, Eric Brouzes, Darren Link
  • Patent number: 10837960
    Abstract: An assay device including a loading zone for a sample that may contain an analyte, an activator in communication with the loading zone from which at least one activator is displaced by presence of the analyte, an amplifier in an inactive state in communication with the activator that becomes activated in the presence of the activator, a biomatrix barrier in communication with the activated amplifier that is degraded or modified by the activated amplifier, and an indicator responsive to the degradation or modification of the biomatrix barrier, which in turn reflects a concentration of the analyte in the sample loaded on the device. The selection of analyte or displacement of the activator by presence of the analyte may occur off-platform and/or may rely on use of non-covalent interactions. The activator may include an enzyme or other reagent that activates the amplifier. Also, associated methods.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: November 17, 2020
    Assignee: CALIFORNIA POLYTECHNIC STATE UNIVERSITY
    Inventors: Nathaniel Martinez, Andres Martinez
  • Patent number: 10835581
    Abstract: A method of treating hyperglycemia, diabetes, metabolic syndrome, insulin resistance (insulin insensitivity), impaired glucose tolerance, high glucose levels, pulmonary hypertension, and/or a condition arising from any of the foregoing in a patient is provided. The method comprises knocking down mARC2 or mARC1 expression in the patient, or otherwise decreasing mARC2 and mARC1 activity in the patient.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: November 17, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Mark Gladwin, Courtney E. Sparacino-Watkins, Michael Jurczak
  • Patent number: 10837014
    Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2 that comprises exon 7. Methods for modulating expression of SMN1 or SMN2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of SMN1 or SMN2.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: November 17, 2020
    Assignee: Translate Bio MA, Inc.
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Patent number: 10830770
    Abstract: The present invention relates to a method for detecting cell death using a luminescent compound; to the luminescent compounds for particular uses; to a kit comprising said compounds and to a protein. The method is applicable for detecting cell death, essentially regardless of the mechanism through which cell death occurred or is occurring and is therefore not limited e.g. to detecting cell death resulting from only one mechanism selected from apoptosis and necrosis.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: November 10, 2020
    Inventors: Markwin Hendrik Maring, Clemens Waltherus Gerardus Löwik, Ermond Reijer Van Beek
  • Patent number: 10829762
    Abstract: Provided are a method for preventing or treating obesity by using a composition including an inhibitor of expression of the Hoga1 gene or an inhibitor of activity of the Hoga1 protein as an active ingredient, and a method of screening a preventive or therapeutic agent for obesity by using the composition.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: November 10, 2020
    Assignees: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, INDUSTRY ACADEMIC COOPERATION FOUNDATION, HALLYM UNIVERSITY
    Inventors: Chu Won Nho, Myung Suk Kim, Chang Ho Jhin, Yoon Shin Cho, Yeongseon Ahn
  • Patent number: 10830772
    Abstract: Uses of ethyl 5,11-dihydroindolo[3,2-b]carbazole-6-carboxylate as a fluorescent ligand probe, preferably in a binding assay for quantitative analysis in combination with a recombinant aryl hydrocarbon receptor (AhR) protein. A method for detection or quantitative analysis of suspected aryl hydrocarbon receptor (AhR) ligands in a sample, the method comprising the steps of: (a) providing a sample possibly containing at least one known or unknown AhR ligand; (b) mixing said sample with a composition comprising a recombinant AhR protein bound to ethyl 5,11-dihydroindolo[3,2-b]carbazole-6-carboxylate; and (c) determining the presence or the total amount of said at least one known or unknown AhR ligand in the sample by fluorescence spectroscopy. Use e.g.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: November 10, 2020
    Assignee: THE EUROPEAN UNION, REPRESENTED BY THE EUROPEAN COMMISSION
    Inventors: Teresa Lettieri, Valentina Elisabetta Viviana Ferrero
  • Patent number: 10822586
    Abstract: Provided herein are methods and assays for isolating and culturing seborrheic keratosis cells ex vivo. Also provided herein are screening assays using cultured seborrheic keratosis cells and methods for treating seborrheic keratosis in a subject.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: November 3, 2020
    Assignee: The General Hospital Corporation
    Inventors: Anna I. Mandinova, Sam W. Lee, Victor A. Neel
  • Patent number: 10822608
    Abstract: Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 3, 2020
    Assignees: Sarepta Therapeutics, Inc., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, University of Maryland, The Progeria Research Foundation
    Inventors: Michael R. Erdos, Francis S. Collins, Kan Cao, Ryszard Kole, Richard Keith Bestwick, Leslie B. Gordon
  • Patent number: 10821128
    Abstract: The present invention relates to the use of a DBait molecules by systemic routes without any combination with an endosomolytic agent.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: November 3, 2020
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Marie Dutreix, Nathalie Berthault
  • Patent number: 10809249
    Abstract: The present invention relates to a method for measuring the cholesterol uptake capacity of lipoproteins. The present invention also relates to a reagent kit for measuring the cholesterol uptake capacity of lipoproteins. The present invention further relates to a tagged cholesterol which can be used in the method and the reagent kit.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: October 20, 2020
    Assignee: SYSMEX CORPORATION
    Inventors: Keiko Yoshikawa, Amane Harada, Katsuhiro Murakami, Maria Kiriyama, Keiko Miwa, Takuya Kubo
  • Patent number: 10799524
    Abstract: This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: October 13, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Martin Koser, Marc Abrams
  • Patent number: 10793858
    Abstract: Ribozymes exhibiting tRNA synthetase activity and substrate specificity, as well as methods for engineering and producing the same, are disclosed. The ribozymes of the present disclosure comprise a T-box module fused with a flexizyme module. The flexizyme module provides high promiscuity with respect to amino acid substrates and the T-box module provides tRNA substrate specificity, which may be engineered as desired. Systems are also described for aminoacylation of suppressor tRNAs with unnatural amino acids (uAAs), such systems comprising the ribozyme previously mentioned, suppressor tRNA, and the desired uAA(s). Methods for incorporating a uAA into a growing polypeptide chain using the ribozyme hereof are also provided.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: October 6, 2020
    Assignees: Purdue Research Foundation, The Regents of the University of California
    Inventors: Barbara L. Golden, Ji Chen, Andrej Luptak, Rui Gan
  • Patent number: 10794898
    Abstract: Methods for identifying a compound that alters fluorescence resonance energy transfer (FRET) of a protein. The methods include use of a genetically engineered cell that includes a target protein. The target protein includes one or more heterologous domains. In one embodiment, a target protein includes two heterologous domains, and in another embodiment, the target protein includes a heterologous domain and the cell further includes a second protein that includes a heterologous domain. A heterologous domain may include a chromophore or an amino acid to which a fluorescent dye attaches. The fluorescence lifetime of one or more chromophore, one or more fluorescent dye, or the combination thereof, is measured after contacting the cell with a compound A difference between the fluorescence lifetime in the presence of the test compound and the fluorescence lifetime in the absence of the test compound indicates that the test compound alters the FRET of the target protein.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: October 6, 2020
    Assignees: Regents of the University of Minnesota, Loyola University Chicago
    Inventors: David D. Thomas, Simon Joseph Gruber, Razvan L. Cornea, Gregory David Gillispie, Kurt C. Peterson, Seth Louis Robia
  • Patent number: 10792298
    Abstract: Pharmaceutical compositions are provided which include a microRNA pool capable of promoting, stimulating or increasing neuronal differentiation, as well as methods for treating, ameliorating and/or preventing depression or diseases where damage to nervous tissue occurs, such as neurological diseases, by means of such microRNA pool.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: October 6, 2020
    Assignee: FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA
    Inventors: Davide De Pietri Tonelli, Meritxell Pons Espinal
  • Patent number: 10787661
    Abstract: A novel method for preparing sequence-verified oligonucleotides is disclosed. In particular, the invention relates to a simple, affordable, and scalable method that combines high-throughput mating of yeast clones, a unique selectable system for combining DNA sequences in yeast, and next-generation sequencing. This method allows sequence-verified oligonucleotides to be readily isolated from complex libraries.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: September 29, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Robert P. St. Onge, Ulrich Schlecht, Sasha F. Levy, Ronald W. Davis, Joseph Horecka